Advances in Plasmonic Technologies for Point of Care Applications by Tokel, Onur et al.
Advances in Plasmonic Technologies for Point of Care Applications
Onur Tokel,†,⊥ Fatih Inci,†,∥ and Utkan Demirci*,†,‡,§,∥
†Demirci Bio-Acoustic-MEMS in Medicine (BAMM) Laboratory, Department of Medicine, Brigham and Women’s Hospital, Harvard
Medical School, Cambridge, Massachusetts 02139, United States
‡Division of Infectious Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 02115, United
States
§Harvard-MIT Health Sciences and Technology, Cambridge, Massachusetts 02139, United States
∥Demirci Bio-Acoustic-MEMS in Medicine (BAMM) Laboratory, Stanford University School of Medicine, Canary Center at Stanford
for Cancer Early Detection, Palo Alto, California 94304, United States
CONTENTS
1. Introduction 5728
2. Overview of Biosensing Technologies 5730
3. SPR Detection Methods 5731
3.1. Fundamental Optical Mechanisms of SPR 5731
3.2. Light Coupling Methods 5732
3.2.1. Prism Coupling 5732
3.2.2. Waveguide Coupling 5732
3.2.3. Diﬀraction Grating Coupling 5732
3.2.4. Photonic-Crystal-Based Coupling 5732
3.2.5. Combined Coupling Methods 5733
3.3. Localized Surface Plasmon Resonance 5733
3.4. Nanoplasmonic Arrays 5734
4. Integration of Plasmonic Technologies with
Microﬂuidics 5735
4.1. Surface Functionalization 5735
4.1.1. Physical Adsorption 5735
4.1.2. Chemical Adsorption and Covalent
Binding 5736
4.1.3. Aﬃnity-Based Interactions 5736
4.2. Blocking of Nonspeciﬁc Binding 5737
4.3. Recent Advances in Surface Functionaliza-
tion 5737
5. Applications of Plasmonic-Based Technologies
for POC: SPR, LSPR, and SPRi 5740
5.1. SPR 5740
5.2. Localized Surface Plasmon Resonance 5741
5.3. Surface Plasmon Resonance Imaging (SPRi) 5743
6. Conclusion and Future Outlook 5746
Author Information 5747
Corresponding Author 5747
Present Address 5747
Notes 5747
Biographies 5747
Acknowledgments 5748
References 5748
1. INTRODUCTION
Demand for accessible and aﬀordable healthcare for infectious
and chronic diseases present signiﬁcant challenges for providing
high-value and eﬀective healthcare. Traditional approaches are
expanding to include point-of-care (POC) diagnostics, bedside
testing, and community-based approaches to respond to these
challenges.1 Innovative solutions utilizing recent advances in
mobile technologies, nanotechnology, imaging systems, and
microﬂuidic technologies are envisioned to assist this trans-
formation.
Infectious diseases have considerable economic and societal
impact on developing settings. For instance, malaria is observed
more commonly in sub-Saharan Africa and India.2 The societal
impact of acquired immune deﬁciency syndrome (AIDS) and
tuberculosis is high, through targeting adults in villages and
leaving behind declining populations.3 In resource-constrained
settings, it is estimated that about 32% of the disease burden is
from communicable diseases such as respiratory infections,
AIDS, and malaria, while 43% of the burden is from
noncommunicable diseases, such as cardiovascular diseases,
neuropsychiatric conditions, and cancer.4 Developing diagnos-
tic platforms that are aﬀordable, robust, and rapid-targeting
infectious diseases is one of the top priorities for improving
healthcare delivery in the developing world.5 The early
detection and monitoring of infectious diseases and cancer
through aﬀordable and accessible healthcare will signiﬁcantly
reduce the disease burden and help preserve the social fabric of
these communities. Further, improved diagnostics and disease
monitoring technologies have potential to enhance foreign
investment, trade, and mobility in the developing countries.6
Highly sensitive and speciﬁc lab assays such as cell culture
methods, polymerase chain reaction (PCR), and enzyme-linked
immunosorbent assay (ELISA) are available for diagnosis of
infectious diseases in the developed world. They require sample
transportation, manual preparation steps, and skilled and well-
trained technicians. These clinical conventional methods
provide results in several hours to days, precluding rapid
detection and response at the primary care settings. Another
diagnostic challenge is identifying multiple pathogens. Since
common symptoms like sore throat and fever can be caused by
multiple infectious agents (e.g., bacteria and viruses), it is
important to accurately identify the responsible agent for
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targeted treatment. Therefore, high-throughput sensors for
multiplexed identiﬁcation would help improve patient care.7
Medical instruments in centrally located institutions in the
developed world rely on uninterrupted electricity and running
water and require controlled environmental conditions. It may
not be viable to satisfy some of these criteria in some POC
settings, where well-trained healthcare personnel are not
available and clean water access is unreliable.7,8 Further, in
remote settings without infrastructure, rain and dust can act as
contaminants.7 Diagnostic devices for POC testing in these
settings are identiﬁed by the World Health Organization to be
aﬀordable, sensitive, user-friendly, speciﬁc to biological agents,
and providing rapid response to small sample volumes.9 Optical
biosensor devices are emerging as powerful biologic agent
detection platforms satisfying these considerations.10
Optical sensing platforms employ various methods, including
refractive index change monitoring, absorption, and spectro-
scopic-based measurements.11 Optical sensors that are based on
refractive index monitoring cover a range of technologies,
including photonic crystal ﬁbers, nano/microring resonator
structures, interferometric devices, plasmonic nano/micro
arrays, and surface plasmon resonance (SPR)-based plat-
forms.11,12 The latter two are plasmonic-based technologies.
Plasmonics is an enabling optical technology with applications
in disease monitoring, diagnostics, homeland security, food
safety, and biological imaging applications. The plasmonic-
based biosensor platforms along with the underlying
technologies are illustrated in the Figure 1. Here, we reviewed
SPR, localized surface plasmon resonance (LSPR), and large-
scale plasmonic arrays (e.g., nanohole arrays).
The integration of plasmonics and microﬂuidic technologies
can potentially serve the global health, primary care, and POC
applications, oﬀering modalities toward inexpensive, robust,
and portable healthcare technologies. Convergence of optical
technologies and microﬂuidic systems is promising for sensor
applications by exploiting ﬂuorescence detection, absorption,
transmission, and polarization measurements on lab-chip
(LOC) systems.13 Microﬂuidics manipulates ﬂuids on the
microscale, minimizing the use of expensive reagents. Further,
inexpensive microchip fabrication potentially allows mass
production.3a,14 Along with the capabilities of sample enrich-
ment, isolation, mixing, and sorting, microﬂuidics has provided
applications in several ﬁelds, including molecular biology,
biotechnology, and defense.15 These characteristics ideally
position microﬂuidics in conjunction with plasmonic tech-
nologies to provide medical solutions at the POC and the
primary care settings.
LOC devices can potentially address the challenges
encountered at POC settings.7 In these devices, single-use
chips retaining the waste can be disposed of after use, avoiding
contamination. The LOC system can be built from relatively
inexpensive parts, speciﬁc to the disease and easy-to-operate
with minimal training. The system can be designed to be
portable, safe, and battery powered. Integrated microﬂuidic
technologies with optical detection platforms such as SPR have
the potential to satisfy characteristics for inexpensive, robust,
and sensitive biosensors.
Here, theory and applications of plasmonic-based platforms
and integration of these technologies with microﬂuidics are
reviewed from a POC diagnostics and monitoring perspective.
First, we compare the plasmonic-based biosensors with other
optical, electrical, or electro-mechanical biosensor technologies.
We describe the theories of SPR and LSPR and demonstrate
the main experimental architecture and operational modes
currently employed. We then discuss in detail the integration of
microﬂuidic platforms, plasmonic technologies, and surface
chemistry techniques leading to LOC devices. We present the
current state-of-the-art plasmonic-based LOC biosensors.
Finally, we provide a perspective on the future of plasmonic
technologies for diagnostics and monitoring of diﬀerent types
of diseases, including infectious diseases and cancer, at the POC
and primary care settings.
Figure 1. Plasmonic-based technologies for versatile biosensor applications. SPR stands for surface plasmon resonance, LSPR for localized surface
plasmon resonance, SPRi for surface plasmon resonance imaging, and SERS for surface-enhanced Raman scattering.
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2. OVERVIEW OF BIOSENSING TECHNOLOGIES
Biosensors have several crucial components: (i) a recognition
element that interacts with the target; (ii) a transducer that
relates the interaction of the recognition element and the target
to a readable electrochemical, optical, acoustic, or piezoelectric
signal; and (iii) a read-out system to interface with this signal.16
SPR, surface-enhanced Raman scattering (SERS), whispering-
gallery modes (WGM), reﬂectometric interference spectrosco-
py (RIfS), and photonic crystals (PC) provide robust and
sensitive optical biosensor platforms. Micro-electro-mechanical
systems (MEMs) or electrical methods also reach to low
detection limits. In particular, cantilever-based sensor tech-
nologies, such as atomic force microscope (AFM), and
electrical sensors, such as electrochemical impedance spectros-
copy (EIS), are alternative detection techniques for biosensing
applications.
SPR and LSPR technologies are based on the wave
propagation or electromagnetic ﬁeld enhancement phenomena
near metal surfaces or nanoparticles. The propagating surface
plasmon polaritons excited on plane metal surfaces are utilized
in SPR sensors. LSPR relies on the ﬁeld enhancement and
conﬁnement in close proximity to nanoparticles. The localized
ﬁeld oscillations around nanoparticles motivate the name
“localized” in LSPR. The plasmon modes extend up to a
couple of hundred nanometers into the biosensor medium in
propagating surface plasmon polaritons (PSPP) and up to a few
tens of nanometers in LSPR sensors, allowing sensitive
subwavelength biosensors.17 SPR biosensors interrogate the
resonance angle changes to detect and quantify bioagents.
LSPR measurements are in the form of absorbance or spectral
shift data obtained from extinction curves. In general,
sensitivities of these resonance or extinction shifts to refractive
index changes are used to quantify ﬁgure of merit parameters
for SPR and LSPR sensors.18
SERS is a surface spectroscopic method providing sensitive
biosensor applications, and it is also a plasmonic technique,
since one of the physical mechanisms behind it is LSPR.19 In
SERS, the total enhancement factor arises from (i) LSPR-
enhanced Raman scattering and (ii) chemical enhancement
factor.20 Experimental biosensing demonstrations of SERS
include detection of bacteria,21 viruses,22 DNA,23 proteins,24
and other small biomolecules.25 Single molecule detection has
been achieved using SERS technology.26 The method inter-
rogates Raman shifts originating from molecular vibrational
energy levels, and therefore, allowing to distinguish structurally
similar molecules if they have distinct vibrational spectra.
Experimentally, the utilization of ﬁber optics and optoﬂuidics,
along with the use of portable spectrometers, holds potential
for future label-free POC applications.27
RIfS, a spectroscopic method, monitors the reﬂected white
light from thin transparent layers.28 The reﬂected light from
each consecutive thin layer acquires a phase shift and the
resulting interference shows peaks and valleys as a function of
wavelength. When bioagents attach to the surface, the
constructive and destructive interference pattern of the
reﬂected light changes. This eﬀect can be used to monitor
real-time binding events. This label-free technology has been
used to detect cancer cells,29 oligonucleotides,30 and glyco-
proteins31 and to acquire kinetic analysis of binding events.32
Another label-free, sensitive optical biosensor is based on the
WGM technology. In this approach, tunable laser light is
usually coupled to microresonators (e.g., ∼100 μm diameter
silica microspheres) through a ﬁber. Part of the incoming light
is guided along the circumference of the resonator. If the light
returns back in phase after every revolution, the guided wave
will drive itself coherently, resulting in a resonance that can be
measured as a dip in the transmission spectra. Bioagents that
are in close proximity of the sensor surface cause this spectral
dip to shift. This wavelength shift can be utilized in pathogen,
DNA, and protein detection applications.33 Single molecule
detection is also demonstrated in modiﬁed WGM experi-
ments.34
Recently, PC technology is being utilized for biosensing
applications. The PCs have a photonic band gap emanating
from the periodicity of the dielectric mediums.35 Light cannot
be coupled to the PCs in the band gap corresponding to a
range of wavelengths. For instance, when light is incident on a
one-dimensional PC, there will be a narrow spectral window
with full reﬂection. Particles that are attached to the PC surface
shift the position of this resonance band.36 The spectral
location of the band gap can be engineered by designing the
Table 1. Comparison of Biosensing Technologies Considering Their Underlying Physical Mechanisms, Multiplexing
Capabilities, and Limit-of-Detection Parameters
technology
physical
mechanism
portability
for POC multiplexing speciﬁcity/analyte limit of detection ref
SPR optical high sensing and imaging bulk solution (1−2.5) × 10−8 RIU 54
microﬂuidics bacteria ∼104−107 CFUs/mL 55
LSPR optical high possible to be combined with
microﬂuidics
human immunodeﬁciency
virus
∼100 copies/mL 56
SERS spectroscopic moderate possible to be combined with
spri
Rhodamine 6G and Crystal
Violet dyes
single molecule 26b,
57
RIfS optical moderate multiwell plates antigen−antibody interactions 19 ng/mL 58
chemical
sensing
thrombine 1.5 pg/mm2 59
WGM optical moderate polarization multiplexing interleukin-2 (IL-2) cytokine
molecule
single molecule 34
PC optical moderate microﬂuidic integration porcine rotavirus 36 virus focus forming units (FFU) or
0.18 × 104 FFU/mL
37
EIS electrical high impedance imaging proteins, antigens, nucleic
acids, antibodies
1−10 fM 44b,
60
human immuno-deﬁciency
virus
106 copies/mL 47
AFM electro-
mechanical
moderate simultaneous imaging and
probing
ligands, streptavidin−biotin
interactions
individual molecular interactions 61
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periodicity of dielectric materials in the PC and by carefully
selecting refractive indices of these materials. PC biosensors
have been developed for label-free detection of bioagents
including viruses,37,38 nucleic acids,39 proteins,40 and cancer
cells.41
Electrical and micro-electro-mechanical sensors provide
alternatives to optical sensing methods. EIS, an electrical
sensing technology, characterizes the frequency response of the
impedance of a chemical system.42 In biosensor applications,
target analytes can be captured on the sensing electrode and the
binding events can be recognized as capacitive changes on this
electrode. Using surface modiﬁed electrodes, various EIS
detection experiments have been performed, including those
on cells,43 nucleic acids,44 bacteria,45 proteins,46 and DNA−
analyte interactions.42 EIS was recently used in human
immunodeﬁciency virus (HIV) detection, where viral load is
a maximum (106−108 copies/mL), through electrical sensing of
viral lysate.47 This label-free method selectively captures
multiple HIV subtypes through anti-gp120 polyclonal antibod-
ies immobilized on the surface of streptavidin-coated magnetic
beads and detects the captured viruses through viral lysate
impedance spectroscopy on-chip. Electro-mechanical canti-
lever-based technologies are primarily used for subnanometer
level imaging as well as in label-free biosensing.48 Label-free
cantilever-based biosensors have been developed for detection
of eukaryotic cells,49 mRNA biomarkers,50 protein conforma-
tions,51 and DNA hybridization.52 Single bacteria and single
nanoparticle detection is also shown by utilizing resonators of
microﬂuidic channels.53
In Table 1, we review these biosensor technologies along
with the SPR technology, taking into consideration the
detection limit, practicality, and multimodality parameters.
Many of these technologies are close to or at the single
molecule detection level, and the application needs to be
evaluated when choosing the appropriate biosensor platform.
3. SPR DETECTION METHODS
3.1. Fundamental Optical Mechanisms of SPR
To analyze the propagation of surface plasmons along a metal−
dielectric boundary, we consider the reﬂection and refraction of
light between two inﬁnite media. A linearly polarized,
monochromatic light propagates from the dielectric medium
toward the metallic surface, as shown in Figure 2. To explain
the SPR theory, transverse magnetic (TM) polarized incident
light is used. TM polarization indicates that the magnetic ﬁeld
vector is in the plane of the metal−dielectric interface. There is
no loss of generality in using TM polarization, since transverse
electric modes cannot excite surface plasmons.62
Solving Maxwell’s equations for the p-polarized light for the
wavevector components, one can ﬁnd the surface plasmon
dispersion relation,63
ω ε ε
ε ε
ω ε
ε ε
=
+
=
+
k
c
k
cz ix
i
1
1 2
1 2
2
1 2 (1)
Here, the medium is indicated by the ﬁrst subscript (i.e., i = 1
for dielectric medium and i = 2 for metal medium), the axis is
indicated by the second subscript, k is the wavevector, ω is the
angular frequency of the light, c is the speed of light in vacuum,
n2 and n1 are the refractive indices for the metal and the
dielectric media, respectively, ε1 = n1
2, ε2 = n2
2, and ε1 and ε2
are the dielectric constants of the media. From the boundary
conditions it also follows that k1z = k2z. Since medium 2 is a
metal, the dielectric constant ε2 and kix are complex-valued
quantities, resulting in the exponential decay of the plasmon
ﬁeld in both media, in the direction of the x-axis. This decay
results in a surface wave, conﬁned to the metal−dielectric
interface. Physically, the incident photons couple to the free
electrons on the interface, resulting in a propagating surface
charge-density oscillation. The k1z component of the wave-
vector deﬁnes the wavelength of the resonance oscillation and
also the extent of the plasmon wave over the interface before
absorption by the metal. For long-range and bound plasmon
waves in an ideal, lossless medium, a real-valued k1z and an
imaginary-valued kix are required, i.e. ε1ε2 < 0 and ε1 + ε2 < 0,
ignoring the imaginary parts of the dielectric constants. At
optical wavelengths these two conditions are satisﬁed for gold
and silver, which are commonly used metals in SPR
experiments.64
Field components of the plasmon modes take their highest
values at the interface and exponentially decay into the metal
and dielectric media. The penetration depth of the ﬁelds into
both mediums are given by 1/Im(k1x) and 1/Im (k2x), where
Im is the imaginary part.63 The penetration depth in the
dielectric media is on the order of half the wavelength of the
incident light. For instance, for a gold−water interface and λ =
700 nm, the penetration depth in water can be calculated to be
around 238 nm.63
When there is a local change in the dielectric constant over
the metal layer, which is caused by a molecular binding event,
the surface plasmon mode energy will be changed. The SPR
biosensors rely on this property of the resonance. Since the
total energy of the system is conserved, the change in the
plasmon mode’s energy will leave a signature on the reﬂected or
transmitted light. In SPR biosensor applications, light is
monitored and analyzed to extract binding and kinetic
information. This analysis is related to which method is utilized
to couple the light to plasmon modes. In the following section,
we overview the main light coupling methods to surface
plasmon modes.
Figure 2. Plane-wave, refracting, and reﬂecting light at a metal−
dielectric interface. n2 and n1 are the refractive indices of the metal and
the dielectric mediums. E is the electric ﬁeld vector, B is the magnetic
ﬁeld vector, and k is the wavevector. The indices i, r, and t are for
incident, reﬂecting and refracting light. The magnetic ﬁeld is
perpendicular to the plane of incidence, representing transverse
magnetic (p-polarized) light.
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3.2. Light Coupling Methods
To excite surface plasmons on a metal−dielectric interface, the
incident light needs to provide photons that would satisfy the
energy and momentum conservation laws in the light−metal
system. More speciﬁcally, the incident photon’s momentum
and energy should match to the momentum and energy of the
plasmon modes to be able to excite these charge-coupled
oscillations. The preceding conditions for plasmon generation
can be satisﬁed simultaneously only when an optical coupling
element is added to the system shown in Figure 2. The
common light coupling techniques utilized for this purpose are
prism, grating, and waveguide coupling methods among other
techniques such as waveguide, photonic crystal, and ﬁber-optic
based coupling.65 Physically, these modiﬁcations take advantage
of attenuated total reﬂection (ATR), light diﬀraction, or
evanescent wave coupling from waveguide modes in these
applications.66
3.2.1. Prism Coupling. Otto conﬁguration and Kretsch-
mann conﬁguration are the pioneering methods of prism
coupling for SPR excitation.67 In these conﬁgurations, a second
dielectric layer (a prism) is added to the two-level system
design considered previously, forming two interfaces. In the
former case, a dielectric layer is sandwiched between a metal
layer and the prism.68 In the latter case, the metal layer is
sandwiched between a prism and the sensing medium.69
A biosensor setup in the Kretschmann conﬁguration is
shown in Figure 3. The addition of a prism provides the
necessary modiﬁcation in the dispersion curves for photon-
plasmon coupling. If the prism dielectric constant ε3 is chosen
such that ε3 > ε1, it is possible to satisfy the energy-momentum
conservation laws for the incident light and plasmon modes,
allowing for surface plasmon excitation on the metal−sensing
medium interface.70 The energy−momentum conserving
equation in the Kretschmann conﬁguration then takes the
following form
ω ε α =
c
ksin( ) Re{ }z3 (2)
where kz is the wavevector for the surface plasmon modes at the
metal−sensing medium interface. Analogous equations for
diﬀerent coupling mechanisms are summarized in Table 2. For
a given light frequency ω, the incidence angle that satisﬁes this
equation is called the plasmon resonance angle. At this
particular resonance angle, the incoming light transfers most
of its energy to the plasmon modes, so the reﬂectivity
approaches to zero at this angle.71 The resonance angle is
sensitive to small changes of the refractive index over the
metal−dielectric interface. This property enables construction
of biosensors that convert the shifts in the resonance angle to
quantitative binding data. For instance, Figure 4A illustrates the
use of a biosensor in the Kretchmann conﬁguration with a
microﬂuidic chip.
3.2.2. Waveguide Coupling. Waveguide structures can be
used for coupling light to excite surface plasmons (Table 2). A
generic waveguide coupling device model is shown in Figure
4B. The propagating wave intensity in the waveguide is
concentrated in the planar waveguide structure, while a small
portion of the light extends through the metal layer to the
metal−sensing medium interface and induces surface plasmons.
This phenomenon is realized in a narrow wavelength range
(resonance wavelength) and presents itself in the transmitted
light spectra.72 Therefore, the wavelength spectra at the output
port of the waveguide can be monitored for biosensing
applications. The shift of the resonance wavelength will allow
quantiﬁcation of the captured agents.73 Fiber-optic-based
coupling approach provides a special case of this method that
the ﬁber-optic cables are cylindrical optical waveguides working
with total internal reﬂection principle. Figure 4C shows a
generic ﬁber-coupled SPR device. The propagating light
bounces from the higher refractive index cladding while
propagating in the lower refractive index core of the ﬁber. A
portion of the cladding can be removed and coated with a thin
metal layer which is in contact with the sensing layer. The
incident light on the metal layer reaches to the metal−sensing
layer interface as an evanescent wave and induces surface
plasmons on this interface.74
3.2.3. Diﬀraction Grating Coupling. Two dimensional
metallic gratings can be used to couple light to plasmon modes
on interfaces. Figure 4D illustrates a grating coupled biosensor
operating in the transmission mode. The momentum-matching
condition becomes a function of the grating order m, an integer
value related to the diﬀracted light direction (Table 2).
Transmitted or reﬂected light from grating coupled plasmonic
biosensors can be studied under intensity, wavelength, or
angular interrogation.75
3.2.4. Photonic-Crystal-Based Coupling. In recent years,
new coupling methods have also been attracting attention.
Various PC-based sensors were realized with planar-waveguide
ﬁbers, microstructured PC ﬁbers, and PC Bragg ﬁbers.76 In the
planar-waveguide structure, the core is covered with a periodic
PC structure (Figure 4E). One side of the waveguide is gold
coated and is in contact with the analyte for plasmonic
detection. The microstructured PCs are being explored in
several design alternatives.77 In general, the ﬁber is made of
silica glass.78 The air-ﬁlled geometric holes provide the periodic
structure for the photonic crystal (Figure 4F). The semicircular
shapes are analyte ﬁlled microchannels. These channels are
gold-coated for surface plasmon excitation and detection. These
Figure 3. A biosensor design in the Kretschmann conﬁguration is
shown. The metal surface (e.g., gold) is functionalized with selective/
speciﬁc recognition elements, for instance with antibodies. Transverse
magnetic polarized incident light is coupled to the surface plasmon
modes on the metal−sensing medium interface. The plasmon waves
propagate in the immediate vicinity of the interface. When the
chemically activated metal surface captures biological samples, the
resulting refractive index change on the surface will modify the surface
plasmon modes. These binding events will leave a signature in the
reﬂected light, which is detected by a detector [e.g., a charge-coupled
device (CCD)] for analysis.
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technologies can be used with microﬂuidics to provide
integrated biosensors.
3.2.5. Combined Coupling Methods. A number of the
preceding methods have been proposed to be used together for
plasmonic biosensor architectures. One example is provided by
the prism-coupled waveguide plasmon excitation scheme.79 In
this method a polymer waveguide is sandwiched between two
metal layers (Figure 4G). A prism is used to couple the incident
light to plasmon modes on one of the metal layers. The
polymer waveguide can be electro-optically modulated to a
desired refractive index. This tuning of the waveguide-coupled
surface plasmon modes makes sensitive surface plasmon angle
interrogation possible by utilizing modulation and demodu-
lation techniques.
3.3. Localized Surface Plasmon Resonance
LSPR sensing is a spectroscopic technique based on the strong
electromagnetic response of metal nanoparticles to refractive
index changes in their immediate vicinity. When light is
incident on nanoparticles, particular electronic modes can be
excited so that the conduction band electrons oscillate
collectively.80 As a result of these resonance oscillations, also
Table 2. SPR Coupling Methods and Coupling Equations
coupling method coupling equationa equation parameters
prism coupling (Kretschmann
conﬁguration)
ω ε α =
c
ksin( ) Re{ }z3
ε3 is the dielectric constant of the prism, c is the speed of light, ω is the angular frequency of the
light, and α is the incidence angle
waveguide coupling β = kRe{ }zwaveguide βwaveguide is the propagation constant for the waveguide mode.
grating coupling π
Λ
+ = ±m k k2 Re{ }z0
Λ is the grating period, k0 is the component of the incident light parallel to the interface, and m is
the grating order.
akz is the wavevector for the surface plasmon modes at the metal-sensing medium interface. Re{} indicates the real part of the argument.
Figure 4. Most common surface plasmon operation modes for light coupling: (A) Kretschmann conﬁguration for prism coupling, (B) waveguide
coupling, (C) ﬁber-optic based coupling, (D) grating coupling, (E) planar waveguide photonic crystal coupling, (F) honeycomb photonic crystal
coupling, (G) waveguide-based coupling in Kretchmann conﬁguration.
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called localized surface plasmons, the nanoparticles strongly
scatter light at a speciﬁc wavelength range. The plasmon
oscillations obtained by solving Maxwell’s equations around
metal nanoparticles are illustrated in Figure 5.81 The sum of
light scattering and absorption is called extinction, and it is
possible to observe the optical response of individual
nanoparticles using dark-ﬁeld microscopy.82 In biosensing
applications, the attachment of an analyte to these nano-
particles results in a refractive index change, causing a red or
blue shift in the extinction peak wavelength, λmax. This shift in
λmax is given by the following equation
83
λΔ ≅ Δ − −m n d l[1 exp( 2 / )]max d (3)
where m is the sensitivity factor, Δn is the change in the
refractive index, d is the eﬀective adsorbate layer thickness, and
ld is the electromagnetic ﬁeld decay length. The extinction is
maximized by optimizing the nanoparticle characteristics
described by m and ld, and it is already well-established that
the extinction is a strong function of the nanometal’s type, size,
shape, and orientation.84 Exploitation and design of these
parameters will be essential for new eﬀective LSPR
applications.84
LSPR sensing experiments utilize a white light source
covering the visible spectrum.85 The scattered light is collected
with a spectrometer, and changes in the spectra are then
converted to binding data.80 In these experiments, light is
directly coupled to the sample without requiring a prism or a
grating, as in the SPR technique; therefore, the angle of
incidence does not need to be precisely controlled. In contrast
to the SPR technique, LSPR sensors based on nanoparticle
surfaces are less sensitive to thermal variations.18a,65,86 In
addition, with the availability of portable spectrometers, it is
likely that LSPR applications can be translated for portable
diagnostic applications.
3.4. Nanoplasmonic Arrays
Array-based nanoplasmonic detection is a plasmonic technique,
similar to SPR imaging (SPRi) in the sense that it can be used
for high-throughput biosensing applications. Various nano-
plasmonic arrays have been demonstrated for refractive-index-
based sensors, including nanoholes,87 nanowells,88 nanoposts,89
nanopillars,90 nanorods,91 nanodisks,92 nanotubes,93 and nano-
pyramids.94 These periodic arrays present high reproducibility
in sensor fabrication, allow spectroscopic and intensity based
measurements, and have a small footprint. A number of
fabrication techniques are used for large-scale arrays, including
focused ion beam milling and soft lithography techniques.95
However, they require expensive fabrication methods that are
not suitable to create inexpensive devices.
Nanohole arrays are usually made from perforated metal
ﬁlms supported on substrates such as silicon nitrides. These
arrays are based on the extraordinary optical transmission
(EOT) eﬀect96 and ﬁnd applications as refractometric
Figure 5. Electric ﬁelds around nanoplasmonic silver particles. (A)
Illustration of the plasmon oscillation and the electron cloud on metal
spheres. (B) Electric ﬁeld contours of the main extinction peak 30 nm
silver spheres in vacuum. Cross section of the sphere is shown with
369 nm light. (C) Electric ﬁeld contours on 60 nm radius silver
spheres in a vacuum. A cross section of the sphere is shown with 358
nm light and the ﬁeld is from the quadropole peak. Adapted with
permission from ref 81. Copyright 2003 American Chemical Society.
Figure 6. A nanohole array integrated with ﬂuidics. The ﬂow-through plasmonic nanostructure enabled local concentration of analytes. The method
presented 100-fold concentration and simultaneous sensing of a protein. Further, the method presented 10-fold improvement in sensing speed in
comparison to the control experiment with no analyte concentration. Reprinted with permission from ref 101a. Copyright 2012 American Chemical
Society.
Chemical Reviews Review
dx.doi.org/10.1021/cr4000623 | Chem. Rev. 2014, 114, 5728−57525734
sensors.97 In nanohole arrays, localized and propagating SPR
modes are intercoupled.98 The resulting resonance modes are
inﬂuenced by the periodicity, size, and shape of holes in the
array and the composition of materials used in the sensor.97a,99
Extensive numerical calculations have been used to gain insight
for the optimization of these parameters.100 These periodic
arrays can be used in the ﬂow-through geometry in biosensors,
which enables concentrating analytes under applied electric
ﬁelds (Figure 6).101 This operation mode lets analytes pass
through the nanochannels, which are also forming the
plasmonic structure of the sensor, and was shown to improve
mass transport properties and response time.87
From a POC perspective, combination of array-based sensors
with microﬂuidic chips can allow high-throughput sensors.
Since each array can be interrogated separately and multiple
arrays on parallel microchannels can be fabricated, nanohole
array sensors are suitable for multiplexed on-chip detection.
Light can be coupled directly to the sensor at or close to
normal incidence, and the transmitted light can be interrogated
with a CCD sensor.102 The imaging mode permits use of high
numerical aperture optics, allowing wide-ﬁeld imaging from
densely packed arrays.103 Microﬂuidic integrated nanohole
arrays have been used for analyzing antibody−ligand binding
kinetics104 and biomarkers.101b A recent application of
nanoholes incorporated 50 microﬂuidic channels (30 μm
width, over a 3.5 × 2 mm area) and utilized high-throughput
SPR imaging.105 The system was used for real-time aﬃnity
measurements.
Capture of intact viruses has been earlier shown from
unprocessed whole blood on microchips.106 Nanoholes have
potential to be used in optoﬂuidic biosensor applications, as
recently demonstrated in the detection of pseudoviruses (i.e.,
pseudotyped Ebola virus) and intact Vaccinia virus at 108 pfu/
mL in PBS.107 However, this platform needs to be expanded to
detect viruses from bodily ﬂuids at clinically relevant
concentrations for diagnostic applications.
4. INTEGRATION OF PLASMONIC TECHNOLOGIES
WITH MICROFLUIDICS
The integration of microﬂuidics and plasmonics brings the
capability to build label-free and reliable biosensors on a LOC
platform. Microﬂuidics has been widely used in cell separation
and isolation and preparation, analysis, and delivery of
samples.85,108 In particular, microﬂuidic technologies for
blood cell separation and plasma isolation are signiﬁcant for
clinical applications.109 Integrated microﬂuidic devices with
various ﬂuid manipulators including pumps, mixing systems,
separators, and valves have already been demonstrated.110
Complete processing and analysis of various bioagents have
been shown on LOC microﬂuidic devices.111 For instance,
DNA puriﬁcation from bacteria on a single microﬂuidic chip
has been shown without either pre- or post-sample
processing.112
Combining microﬂuidics with optics provides a rapidly
expanding range of applications by bringing advantages from
these ﬁelds. Microﬂuidic-based plasmonic devices are refractive
index monitoring type devices. This class of devices can be
considered as a subtype of optoﬂuidics devices. On one hand,
light can be used to direct the motion of ﬂuids in microﬂuidic
chips. Optical-tweezers-based approaches have been used to
build valves and pumps to induce ﬂow in microﬂuidic
channels.113 Blood cell separation has been demonstrated by
utilizing optical lattices.114 On the other hand, ﬂuids can be
used to alter optical parameters, as in plasmonics. Refractive
index, absorption, polarization, and spectral properties can be
monitored for various plasmonic biosensor designs. A further
advantage of plasmonics is to allow label-free signal trans-
duction method.
The two main optical biosensor design considerations are
light−analyte interaction volume and sample delivery, which
can seriously constrain the use of biosensors. The former
consideration can be addressed by plasmonics taking advantage
of the evanescent electromagnetic ﬁelds. For instance, the
evanescent ﬁelds generated by the surface plasmon polaritons
in SPR extend a few hundred nanometers into the ﬂuid and
allow low analyte densities to be detected. The latter
consideration can be addressed by microﬂuidics, which can
manipulate microliter quantities of ﬂuids.115 Further, selective
delivery of analytes through multiple channels can be
engineered for high-throughput microﬂuidic applications.
In plasmonic-based LOC biosensors, a recognition element is
immobilized on the detection surface for label-free sensing. The
choice of the recognition element depends on a number of
factors, including the speciﬁcity and aﬃnity toward the target
molecule. Further, the complex formation between the
recognition element and the target molecules should be stable
in structure. Various surface functionalization techniques exist
for the immobilization of these moieties for stable, high-density
and eﬃcient binding. We review these techniques in the
following section.
4.1. Surface Functionalization
Biosensing platforms are comprised of a sensing support
surface (e.g., gold and silver) and an immobilized biomolecular
recognition element (e.g., antibodies, oligonucleic acids,
peptide nucleic acids, peptides, and polymers).116 The support
surface enables the recognition element to be stable and allows
them to interact with the target analytes. Depending on the
sensitivity, speciﬁcity, and limit of detection, the recognition
element is immobilized through several surface techniques,
including physical adsorption, chemical adsorption, covalent
binding, and aﬃnity-based interactions.116a Besides these
common methods, recent advances in surface functionalization
and antifouling agents to minimize nonspeciﬁc binding are also
reviewed in the following subsections.
4.1.1. Physical Adsorption. Physical adsorption technique
utilizes the surface characteristics and surface charge to attach
and immobilize biorecognition elements onto the surface and
relies on nonspeciﬁc physical interactions between the
recognition element and the support material.117 In contrast
to chemical binding techniques, this method also holds a key
advantage since it does not require any reagent to activate
chemical groups on the surface, and thus, this technique is easy
to perform, inexpensive, and reduces structural damage in
biorecognition elements. The physical adsorption method
particularly utilizes hydrogen bonding and van der Waals
forces.118 These weak interactions also allow the biorecognition
elements to easily detach from the surface, and thus, the
biosensing surface can be used multiple times. However,
nonspeciﬁc physical interactions are closely aﬀected by
environmental changes, including temperature, ionic content,
and pH. On the other hand, this technique causes nonspeciﬁc
binding of other molecules and substances, resulting in a
signiﬁcant decrease in surface coverage of the recognition
elements and sensor speciﬁcity.
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The support materials can be modiﬁed to generate surface
charge and reactive groups using oxidizing techniques such as
oxygen plasma treatment. Oxygen-plasma-treated and un-
treated polystyrene (PS) slides have been recently used as
sensor substrates to detect breast cancer type 1 (BRCA1) gene
mutations, and these two cases were compared in terms of
uniform immobilization and binding capacity of a biorecogni-
tion element (i.e., oligonucleotide−protein conjugate).119 On
plasma-treated slides, the binding amount of oligonucleotide−
protein conjugates signiﬁcantly increased compared to un-
treated slides.119 Another interesting observation in this study
was that plasma treatment ampliﬁed the surface area and
formed nanoroughened structures that could facilitate detection
of a low amount of target analyte and improve the analytical
performance of the biosensing surface in microarray
applications.119 Although oxygen plasma treatment is a simple
and eﬀective method for many surfaces, it often causes
signiﬁcant damage on the biosensing support surface.120 This
major obstacle leads to permanent surface disruptions, which
interfere with the sensor surface structure and reduce
sensitivity.120 On the other hand, the surface characteristics
(e.g., hydrophobicity and polarity) and the functional groups of
biomolecules determine the molecular interactions for bio-
molecule immobilization. Although, in some cases, the
orientation of the recognition element is not critical to capture
the target analyte, these molecular changes on the surface can
aﬀect biomolecular activity (e.g., denaturation of proteins) and
orientation of proteins and antibodies due to the restrictions in
their conformational ﬂexibility.121
4.1.2. Chemical Adsorption and Covalent Binding.
Chemical adsorption and covalent binding techniques are most
frequently combined to form chemical coupling and bond
formation between support surface and biorecognition
elements in three main steps: (i) support surface activation,
(ii) functional group generation, and (iii) biomolecule
immobilization.116a The self-assembled monolayer (SAM)
technique, one of the most common chemical adsorption
techniques (i.e., chemisorption), spontaneously generates self-
formation of molecular assemblies on substrates.122 N-
alkylthiols or disulﬁdes are the most common SAM molecules,
consisting of an alkyl backbone chain, thiol head, and functional
tail groups.116a,123 On these molecules, thiol head groups have
strong aﬃnity to bind to metal surfaces (e.g., gold and silver),
and the alkyl backbone tethers the biomolecules from the
substrate. The latter group presents a functional end to interact
and covalently bind to biomolecules.116a Coupling reactions
(e .g . , N -hydroxysucc in imide (NHS) and e thy l -
(dimethylaminopropyl)carbodiimide (EDC)) are the most
common biomolecule immobilization methods that typically
form succinimide groups that interact with amine groups of
organic molecules (e.g., antibody, protein, nucleic acids, and
amine-modiﬁed lipids).124 By utilizing covalent bonding,
modiﬁed SAM agents (e.g., 11-mercaptoundecylamine
(MUAM) and dithiobis(N-succinimidyl propionate) (DTSP))
were previously used to immobilize double-stranded DNA,
peptide nucleic acid (PNA), and miRNA on SPR gold sensors
for the detection of nucleic acids.125 Other than the SAM
mechanism, biomolecules can be immobilized through
silanization agents (e.g., (3-aminopropyl)triethoxysilane
(APTES) and (3-aminopropyl)trimethoxysilane−tetramethox-
ysilane (MPTMS or 3-MPS)) that cover a biosensing surface
(e.g., glass, mica, metal oxides, and silica) with functional
alkoxysilane molecules by forming a covalent Si−O−Si
bond.108c,126 This process can also be coupled with another
reaction as performed in SAM modiﬁcations.108c,121,127 On the
same platform, long- and short-chained SAMs can also be
utilized to block the surface from nonspeciﬁc binding.128
Further, long-chained SAMs can be used to construct artiﬁcial
lipid bilayer systems using hydrophobic interactions between
alkyl backbones and lipid tails.129 For instance, artiﬁcial lipid
bilayers are constructed by the rupture of liposomes, and self-
assembled hexadecane monolayer surface assists to rupture
liposomes for the formation of lipid bilayers on gold surfaces.129
Thus, self-assembled hexadecane monolayer surface provides a
dynamic and stable structure to tether lipid bilayer and allows
for further biomolecular analyses such as polymer−lipid bilayer
interaction in vitro conditions.129 Additionally, SAMs can be
used to immobilize protein conjugate, oligonucleic acids, and
peptide nucleic acids for microarray analysis.130 However, there
are some limitations in SAM formation, including availability of
substrate, low number of organic molecules for monolayer
formation, the choice of anchoring groups, and limited
solubility of monolayer molecules.122 Additionally, bulky
monolayer molecules result in large defects in monolayer
structure and lack of thermal and oxidative stability restricting
their large-scale use in detection platforms.122
4.1.3. Aﬃnity-Based Interactions. Aﬃnity-based surface
functionalization techniques address some of the current
challenges in biomolecule immobilization methods mentioned
above. Avidin−biotin-based interactions are commonly used to
immobilize biomolecules (e.g., nucleic acids, proteins, and
antibodies) on the biosensing surface without interfering with
their biomolecular structure and function.106b For instance,
NeutrAvidin and streptavidin are well-known members of
avidin proteins, and they have high association capacity to
biotinylated molecules such as antibodies, nucleic acids,
peptides, and PNA. An interesting example for biotin−avidin-
based surface functionalization is traptavidin, which is an
engineered mutant version of streptavidin protein according to
biotin−4-ﬂuorescein dissociation rate.131 This mutant avidin
protein has lower ﬂexibility in the biotin-binding pocket, and
this structural property reduces the entropic energy required for
biotin binding.131 Thus, traptavidin structurally inhibits the
dissociation rate and enhances thermostability compared to
native avidin proteins. Traptavidin is also a versatile protein that
can bind to a range of biotin conjugates (i.e., biotin−4-
ﬂuorescein, biotin−amidocaproyl-BSA and biotinylated DNA
(internal and terminal)).131 Therefore, this protein holds a
great potential to replace other avidin-based proteins in
nanoplasmonic detection platforms, molecular anchored arrays,
and POC diagnostic technology platforms.131 However, the
biotinylation site is a critical parameter for biomolecule (e.g.,
antibody) orientation in avidin−biotin-based surface chem-
istries. Two groups of aﬃnity-based surface chemistries (i.e.,
protein G- and NeutrAvidin-based) were evaluated, and the
observations obtained from AFM demonstrate that protein G-
based surface chemistry can eﬃciently immobilize the antibod-
ies with their favorable orientation in microﬂuidic channels.106b
Since protein G has a speciﬁc binding site for the fragment
crystallizable region (Fc) of antibodies, it provides better
control over antibody orientation.106b To increase the number
of antibody binding sites and stability, immunoglobin speciﬁc
proteins are engineered using recombinant DNA technology.
Protein A/G is a notable example of the recombinant antibody
immobilization molecules that combines IgG binding domains
of both protein A and protein G. This recombinant fusion
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protein is comprised of four Fc binding domains from protein
A and two from protein G, and it is more stable to pH changes
compared to protein A.107,132 Overall, aﬃnity-based surface
functionalization methods increase sensitivity and capture
eﬃciency and improve the detection limit to capture target
molecules/bioagents by utilizing high binding aﬃnity and
controlling molecular orientation. Additionally, oligonucleotide
immobilization for nucleic acid hybridization studies and
histidine-chelated metal ion methods for protein-based
detection are widely used in the immobilization of
biorecognition elements.133 There are also new surface
functionalization methods, including polymeric coating, lipid
bilayer construction, PNA, and aptamer immobilization, to
capture target analytes in POC and primary care diagnostics for
various applications ranging from early cancer detection
diagnosis and monitoring of infectious diseases.
4.2. Blocking of Nonspeciﬁc Binding
Nonspeciﬁc binding to biosensing surfaces is one of the major
drawbacks for speciﬁc capture and quantitative analysis.134 One
of the challenges is the concentration of other substances being
higher than target analyte since these substances can also bind/
attach to the biosensing area.135 Although the binding
characteristics of nonspeciﬁc interactions is much diﬀerent
than that for a speciﬁc binding event, nonspeciﬁc interactions
and binding still poses a signiﬁcant bottleneck for limit-of-
detection in biosensors. Further, nonspeciﬁc binding can occur
at functionalized, passivated, and untreated regions of the
biosensing area.135 Thus, these nonspeciﬁc interactions can
decrease detection sensitivity. There are several antifouling
agents (e.g., chemical, protein based, and polymeric agents)
used to address these challenges by improving the speciﬁcity.
Thiol compounds have been commonly used as chemical
blocking agents on metal surfaces. The length and terminal
group of thiol compounds aﬀect the sensitivity and detection
limit.136 To evaluate these parameters, a number of alkanethiol
SAMs (i.e., 3-mercapto-1-propanol (3-MPL), 6-mercapto-1-
hexanol (6-MHL), 8-mercapto-1-octanol (8-MOL), 9-mercap-
to-1-nonanol (9-MNL), 11-mercapto-1-undecanol (11-MUL)
and another blocking thiol (C11) with a −CH3 terminating
headgroup, and 1-dodecanethiol (1-DDT)) was used for the
detection of the target DNA sequences using pyrrolidinyl
peptide nucleotide acid (acpcPNA) probes that were
immobilized via a spacer molecule.136 The blocking thiol
compound with same length (9-MNL) as the total spacer
molecule provided the highest sensitivity [20.4 ± 0.7 nF cm−2
(log M)−1] compared to the other thiol blocking agents with
shorter and longer length.136 This speciﬁc length possibly
arranged more favorable hybridization, resulting in the highest
hybridization eﬃciency, whereas the blocking agent with longer
length overlapped with the probe.136 The terminal groups (i.e.,
−OH and −CH3) of thiol blocking agents were also evaluated
on the same platform, and the hydroxyl-terminated agent
provided a slightly better sensitivity by increasing hydrophilicity
for DNA immobilization and hybridization.136 Proteins (e.g.,
bovine serum albumin, casein, glycine, and gelatin) have been
also used to protect the biosensing surface from nonspeciﬁc
interactions. Instantized dry milk, casein, gelatins from pig and
ﬁsh skin, and serum albumin were evaluated to understand the
blocking capabilities, and casein and instantized milk were
observed to inhibit nonspeciﬁc binding.137 In this study,
porcine skin gelatin was observed to be the least eﬀective
antifouling agent.137 Overall, the critical parameter for protein
blocking experiments is that blocking agent (e.g., casein)
primarily interacts with the biosensing area instead of blocking
the protein−protein interactions observed in porcine skin
gelatin experiments.137 However, the eﬃciency of these natural
blocking agents (e.g., albumin, casein, and glycine) is not
considerably satisfactory.138 In contrast, polymeric blocking
agents are easily reproducible and can be modiﬁed to increase
the speciﬁcity of blocking.138 Polyethylene glycol (PEG) is one
of the most common polymeric blocking agents, and a densely
packed PEG tethered-chain surface allows one to minimize
nonspeciﬁc binding.138,139 The combination of long and short
PEG chains signiﬁcantly reduces biofouling on the biosensing
surface and increases the sensitivity.138,140 Factor IX (FIX) was
immobilized on glutaraldehyde-activated surface and detected
via its aptamer.138 A copolymer (i.e., poly(ethylene glycol)-b-
poly(acrylic acid) (PEG-b-PAAc)) was used as a blocking agent
to reduce nonspeciﬁc binding on untreated and glutaraldehyde-
activated regions.138 The limit of detection was observed to be
down to 100 pM.138 The sensitivity was further improved by
using dual polymers (i.e., PEG-b-PAAc and pentaethylenehex-
amine-terminated PEG (N6-PEG)) on the same platform, and
1000-fold better sensitivity (100 fM) was achieved with respect
to the blocking with PEG-b-PAAc.138 Here, the use of dual
polymers demonstrates higher sensitivity and reliability for the
biosensing platforms that detect a very small amount of target
molecules from complex ﬂuids such as whole blood.138 Apart
from these surface modiﬁcations, the generation of nanorough
surfaces allows one to prevent the bacterial attachment on
biosensing surface.141
4.3. Recent Advances in Surface Functionalization
Within the past decade, conventional surface functionalization
methods have been replaced with new surface modiﬁcation
materials (e.g., lipids and polymers) and techniques (e.g., thiol
exchange and site-speciﬁc functionalization). These innovations
improve the molecular interactions between target molecule
and the receptor of interest, and they enable more stable
structures for biosensing platforms.142 For instance, receptors
(e.g., integral proteins) incorporated with cellular membranes
require hydrophobic content to conserve their native structure
and function in biosensing platforms.142c Dynamic, ﬂexible, and
complex nature of the cellular membranes is an attractive
candidate to support biorecognition elements such as receptors
for these platforms.142c Noncovalent assembly of lipid bilayers
on biosensing surfaces combines highly sophisticated surface
modiﬁcation mechanisms with a nature-synthesized functional
platform.142c The arrangements of lipid bilayers also allow one
to monitor membrane-associated molecular recognition events
on the close vicinity of the membrane using surface sensitive
tools such as LSPR and SPR.142c To construct lipid bilayers on
biosensing platforms, speciﬁc surface immobilization strategies
are employed using tethering agents that rupture lipid vesicles
to form a planar lipid bilayer.142b,143 This strategy can be done
by utilizing a thin layer of SiO2 on plasmonic substrate.
144
Other construction strategies are the use of thiolated lipids that
covalently immobilize lipid membrane to metal substrate and
utilization of a polymer cushion that tethers lipid membrane
and forms an ionic reservoir for functional integration of
receptors.145
Chemical modiﬁcation and physical properties of lipid
molecules have allowed lipid bilayers to be used in surface
sensitive biosensing approaches, including the detection of
biomolecules, proteins, and nucleic acids. Biotinylated-lipid
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Figure 7. Recent advances in surface functionalization methods and materials. (A) Lipid-supported surface functionalization and applications: (i)
Schematic of a gold nanorod coated with a biotinylated lipid membrane and interactions with streptavidin. Adapted with permission from ref 146.
Copyright 2008 American Chemical Society. (ii) Schematic of supported lipid-bilayer-coated core shell nanocubes (Ag@SiO2). TEM images of
whole and select region of a Ag@SiO2 nanocube. A solution-phase plasmonic sensor measures LSPR spectra of surface modiﬁcation and coating on
Ag@SiO2 core shell nanocubes using a standard laboratory spectroscopy. Adapted with permission from ref 147. Copyright 2012 Nature Publishing
Group. (iii) Schematic of lipid-bilayer-coated nanopore in silicon nitride substrate. This platform facilitates mobility of target molecules and
minimizes clogging. Adapted with permission from ref 150. Copyright 2011 Nature Publishing Group. (B) Lipid-supported surface functionalization
and applications: (i) The procedure of a gold-nanoparticle-hybridized polymer ﬁlm for biosensing applications. Adapted with permission from ref
151. Copyright 2009 Wiley-VCH Verlag GmbH & Co. KGaA. (ii) SPR-based biosensing platform with embedded indium tin oxide microheater and
rapid tuning of SPR signal using a thermoresponsive polymer (i.e., pNIPAAm). Reprinted with permission from ref 152. Copyright 2013 American
Chemical Society. (C) Surface functionalization on patterned surfaces: (i) Schematic and scanning electron microscopy (SEM) image of the
patterned nanostructures (i.e., nanoholes). (ii) SEM top-view image of nanholes and extinction peak values of LSPR spectra for surface
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membranes were immobilized to detect streptavidin molecules
on the surface of gold nanorods by monitoring the spectral
shifts using a fast single particle spectroscopy (fastSPS)
instrument coupled with dark-ﬁeld microscopy (Figure 7A-
A(i)).146 The binding of streptavidin molecules to a single
nanorod resulted in a median shift of 2.9 ± 1.8 nm when 29
nanorods were analyzed.146 Thus, on this platform, local
interactions of proteins with cellular membranes could be
monitored in real-time.146 Another interesting example was to
assess the binding of target proteins to supported lipid-
membrane-coated nanocubes (Figure 7A(ii)).147 Here, the
researchers reported a solution-phase plasmonic sensor method
that utilizes LSPR spectra of Ag@SiO2 core shell nanocubes
using spectroscopic measurements (Figure 7A(ii)).147 In this
work, supported lipid bilayers were spontaneously formed by
mixing Ag@SiO2 core shell nanocubes in lipid-vesicle solution,
and the plasmonic response of the platform was calibrated by
examining the binding of streptavidin to biotinylated lipid
molecules in the supported membrane. LSPR response was
then converted to protein coverage on the nanocube surface by
utilizing the LSPR shifts to protein mass change, and the limit
of detection was reported as 0.191 ng/mm2 nm.147 Further,
cellular-membrane-associated molecular interactions were
assessed on the supported lipid-bilayer-modiﬁed gold nano-
particles using a single nanoparticle tracking-based detection
method.148 The binding and molecular interactions of
membrane-associated molecules (i.e., cholera toxin B subunit
and ganglioside GM1 pentasaccharide head-groups) were
evaluated using the diﬀusion coeﬃcients of gold nanoparticles
on the membrane.148 The limit of detection for the cholera
toxin B subunit was observed to be down to 10 pM, resulting in
100-fold improvement in the sensitivity compared to
ﬂuorophore-based methods.148 Thus, an ultrasensitive detec-
tion platform was developed by utilizing the mobility of lipid
molecules in membranes.148 Additionally, supported lipid
membranes were employed on nanopore assays for the
detection of small molecules (e.g., proteins) and the monitoring
of DNA hybridization and receptor−target interactions.142c,149
The integration of lipid bilayers with nanohole platforms
facilitated more frequent translocation/mobility of target
molecules and, thus, introduced chemical sensitivity and
avoided clogging, which are major obstacles in biosensing
assays (Figure 7A(iii)).142c,150 Overall, lipid-bilayer-incorpo-
rated biosensing platforms improve the molecular interactions
and form a support layer for the integration of biorecognition
elements. Thus, this new surface functionalization strategy can
be used for membrane-associated molecule biosensors and
toxin/drug screening assays in the future.
Polymer-mediated surface functionalization is another
interesting strategy to generate a support layer for the
immobilization of biorecognition elements. Polymers play a
vital role to enhance the reliability and sensitivity of biosensors,
and they are often used for hybridization with plasmonic
nanoparticles (Figure 7B(i)).151 For instance, a polymer-
assisted plasmonic sensor was developed by hybridizing
polyelectrolyte multilayers (PEMs) with gold nanoparticles to
real-time monitor the binding of antigen−antibody on
plasmonic sensors (Figure 7B(i)).151 This hybrid ﬁlm
presented a stable and reliable nanoporous structure under
physiological conditions and enhanced the surface area for
bioconjugation and recognition.151 Further, PEMs exhibited an
antifouling property to prevent nonspeciﬁc binding of proteins
and cells that enhanced detection sensitivity.151 To utilize
dynamic structure of polymers, thermoresponsive poly(N-
isopropylacrylamide) (pNIPAAm)-based hydrogel was imple-
mented as SPR sensors for rapid tuning of SPR signal (Figure
7B(ii)).152 Here, an indium tin oxide microheater was
embedded under the SPR sensor, and thus, rapid thermal
response (i.e., swelling and collapse) of pNIPAAm was
evaluated (Figure 7B(ii)).152 Thermal response of pNIPAAm
led to large refractive index changes and a high thermo-optical
coeﬃcient of dn/dT = 2 × 10−2 RIU/K.152 Further, polymers
can be modiﬁed with biorecognition elements for speciﬁc
capture of target molecules, and thus, a 3D binding matrix can
be developed for biosensing applications by utilizing dynamic
and functional structure of polymers.152,153,154
Recently, the researchers have taken advantage of the
plasmonic surface geometry for surface functionalization.
Patterned nanoplasmonic structures with specialized geo-
metries (e.g., holes and edges) exhibit a potential to be used
for site-speciﬁc surface modiﬁcations that can increase the
utility and speciﬁcity of nanoplasmonic platforms.142b Partic-
ularly, nanoplasmonic platforms employ noble metal surfaces
(e.g., gold and silver) that can be modiﬁed using thiol chemistry
to immobilize biorecognition elements.155 Thiol chemistry also
presents a broad range of variety in length, saturation degree,
and terminal groups to preferably immobilize recognition
elements (e.g., proteins, nucleotides, and carbohydrates) in
plasmonically active zones.142b,156 The thiol exchange process is
an interesting strategy to selectively immobilize antibodies on
the edges of triangular gold nanoplates that are used for LSPR
sensing platform.142a The thiols located on the edges of the
nanoplates are more attractive to exchange with the thiols in
solution than the ones located on the ﬂat surfaces of the
nanoplates due to decreased steric hindrance at high-curvature
sites.142b,157 Other than patterned nanoplasmonic structures,
hybrid noble metal layers can also be selectively functionalized
for biosensing platforms (Figure 7C). Recently, nanohole arrays
consisting of TiO2/Au/TiO2 ﬁlms were speciﬁcally modiﬁed
with poly-L-lysine−poly(ethylene glycol) (PLL−PEG) and
thiolated PEG (HS-PEG) molecules (Figure 7C(i,ii)).158
PLL−PEG selectively adsorbed to the TiO2 layers (i.e., top
and bottom layers), and HS-PEG covalently bound to gold
layer (i.e., intersectional layer) (Figure 7C(iii)).158 HS-PEG
molecules were then functionalized with biotin for the selective
detection of avidin on the hole sidewalls (Figure 7C(iii)).158
This site-speciﬁc functionalization mechanism enabled the
increase of the signal change per unit time for avidin−biotin
binding nearly 20-fold (Figure 7C(iii)).158 In the future, this
functionalization strategy will play a key role for the
improvement of sensitivity and the development of multiplex
assays by enabling speciﬁc modiﬁcations on plasmonically
active sites. Overall, surface functionalization is one of the key
Figure 7. continued
modiﬁcations. (iii) Nanoholes arrays consisting of TiO2/Au/TiO2 ﬁlms are speciﬁcally modiﬁed with poly-L-lysine−poly(ethylene glycol) (PLL−
PEG) and thiolated PEG (HS-PEG) molecules for site-speciﬁc surface functionalization. Adapted with permission from ref 158. Copyright 2010
American Chemical Society.
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parameters to develop a sensitive, reliable, and accurate
biosensing platform.
5. APPLICATIONS OF PLASMONIC-BASED
TECHNOLOGIES FOR POC: SPR, LSPR, AND SPRi
5.1. SPR
SPR has been used in a broad range of biosensing applications,
including detection of bacteria, viruses, eukaryotic cells, nucleic
acids, peptide nucleic acids, proteins, and drugs, and in
monitoring of biomolecular interactions such as nucleic acid
hybridization or protein−ligand interaction.55
Another important potential clinical application of SPR is in
cancer diagnosis. Cancer is a signiﬁcant problem both in the
developed and developing world.159 In 2008, ∼12.7 million
cancer cases and 7.6 million cancer deaths occurred worldwide,
and 56% of the cases and 64% of the deaths were reported in
developing countries.159 Although overall cancer incidence
rates in developed countries are higher than those observed in
developing countries, cancer mortality rates are usually similar
between developed and developing countries.159,160 Some of
the most critical cancers in the developing world are female
breast (27.3%), stomach (15.3%), lung (19.1%), colorectal
(10.7%), and cervical (17.8%) cancers.161 Early detection of
cancer is a critical need in medicine, especially for cancer types
such as breast, cervical, ovarian, and colorectal cancers.160,162
Rapid available technologies to monitor early cancer markers
supported by our advanced understanding of cancer and
discovery of speciﬁc biomarkers will enhance the capabilities in
cancer detection. Detection platform technologies could serve
diverse clinical needs in early cancer detection and diagnosis
(for instance by detecting circulating tumor cells163) or
monitoring cancer treatment. In addition, these platforms
could be inexpensive, rapid, portable, and easy to operate in
developing countries as well as in developed settings, creating
potentially broad screening tools for applicable cancer types.
From a diagnostic perspective, detection of circulating
biomarkers for cancer diagnosis is an interesting application
of SPR-based detection platforms. For instance, cytokine
interleukin-8 (IL-8) plays a crucial role in human cancer.164
The diﬀerentiations in IL-8 expression level result in multiple
human cancers, such as breast cancer, Hodgkin’s lymphoma,
and prostate cancer.164 IL-8 concentration in saliva was shown
to be elevated in oropharyngeal squamous cell carcinoma
(OSCC) patients.165 To detect the IL-8 concentrations in
human saliva, a microﬂuidic SPR-based immunoassay platform
was developed.166 For this experiment, two monoclonal
antibodies were used as a sandwich assay to detect diﬀerent
epitopes on the antigen (IL-8) in either buﬀer or saliva samples.
This platform presented a 250 pM limit-of-detection in saliva
environment.166 IL-8 levels in healthy individuals saliva are 30
pM whereas the levels in oral cancer patients’ saliva are 86
pM.166 By preconcentrating the saliva in sample preparation
steps, the system could potentially be used in diagnostics as
well.
Another attractive biomarker detection experiment was
performed for prostate-speciﬁc antigen (PSA). The increase
in the levels of PSA (>4 ng/mL) in patient samples is one of
the symptoms for possible prostate malignancy.167 On the
other hand, PSA has been reported as a potential marker for
breast cancer in women.168 To detect PSA levels a sandwich
bioassay was developed.169 Basically, anti-PSA antibodies were
immobilized on the Au layer of the sensor surface. After the
sampling, Au nanoparticles coated with a secondary antibody
were applied to increase the SPR signal levels. In one
Figure 8. Portable SPR biosensor platforms. (A) A multichannel cartridge to be used for on-site antibiotic detection in milk samples. Reprinted with
permission from ref 171. Copyright 2010 Elsevier. (B) Portable SPR biosensor prototype to be used with microﬂuidic chips. Reprinted with
permission from ref 172. Copyright 2009 Elsevier. (C) Portable microﬂuidic-based device for cardiac marker detection. Reprinted with permission
from ref 173. Copyright 2006 American Chemical Society.
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experiment, 300 fM of PSA in PBS was detected using 20 nm
Au nanoparticles.169 In a similar study, diﬀerent sizes of Au
nanoparticles were evaluated in serum samples. For 20 and 40
nm Au nanoparticles, limit-of-detection was observed as 2.3 and
0.29 ng/mL (8.5 pM) in human serum, respectively.170 The
latter detection limit is reported to cover the threshold value
required for diagnosing prostate cancer.170
A portable microﬂuidic-based SPR device was developed for
analysis of antibiotics in milk. A disposable microﬂuidic
cartridge incorporating six microchannels used in this device
is illustrated in Figure 8A.171 The chips were activated with self-
assembled monolayers and then biofunctionalized to detect
samples from ﬂuoroquinolone, sulfonamide, and phenicol
antibiotic families. The detection limit of the antibiotics in
the former antibiotic families was around 2 μg/L with milk
diluted by one-ﬁfth in PBS, which is lower than the minimum
required level (MRL) set by European Union regulations. The
detection limit for the latter family was found to be 1.1 μg/L,
which is slightly over the MRL of 0.3 μg/L. The platform does
not require any sample preprocessing except dilution, and the
process assay time is reported to take ∼30 min per sample.
A prototype hand-held SPR-based device was developed and
applied to biotoxin detection (Figure 8B).172 The device
incorporated a plastic ﬂow cell as the detection medium, which
can be replaced by a microﬂuidic chip in future versions. A
photodiode array was used to capture the reﬂected light from
the prism used in the Kretschmann conﬁguration. The system
detected ricin, a highly toxic protein, with a 200 ng/mL limit of
detection compared to the 10 ng/mL performance of a
commercial Biacore device. The main advantages of the system
are its portability and battery operability, which are signiﬁcant
needs for POC diagnostics in resource-constrained settings.
Researchers have also followed the path of modifying some
of the available commercial SPR devices for biosensing
applications. For instance, SPR equipment (NTT Advanced,
Tokyo, Japan) setup in the Kretschmann conﬁguration was
arranged to work with a polydimethylsiloxane (PDMS)
microﬂuidic chip for the detection of B-type natriuretic peptide
(BNP) as a cardiac biomarker.173 The researchers developed a
sensitive labeled immunoassay to be used in a portable SPR
device. A detection level of 10 pg/mL in serum was
demonstrated.173 It is reported that the patient blood BNP
levels range from ∼20 pg/mL to 2 ng/mL; therefore, the
platform could potentially be useful for clinical use.173 This
device is illustrated in Figure 8C. Another example to this
strategy is demonstrated by the modiﬁcation of a Spreeta 2000
device (Texas Instruments) to develop a portable 24-analyte
biosensor.174
5.2. Localized Surface Plasmon Resonance
LSPR has been used in measurements of binding kinetics,84a,175
conformational changes,176 and molecular sensors,177 and it is
further exploited in nanoscale photonics.178 The solution-phase
nanoparticle sensing takes advantage of the dipole interactions
between the nanoparticles when attached to target molecules.
For example, when nanoparticles are hybridized to DNA targets
and brought closer in solution, the LSPR modes of gold
nanoparticles are coupled, and an enhanced extinction is
observed. Distinguishing DNA target sequences that contain
single nucleotide mismatches or deletions has been possible
with this method, and an increase of sensitivity of 2 orders of
magnitude compared to ﬂuorescence-based assays has been
reported.179 Since this mode coupling is a function of distance
between nanoparticles, it is possible to measure DNA strand
lengths.176a,180
An alternative path is to synthesize arrays of nanoparticles on
solid substrates and tailor their properties to optimize the
extinction. Nanosphere lithography (NSL) is a rapid self-
assembly chemical synthesis technique providing a cost-
eﬀective alternative to conventional lithographical techniques
for creating periodic array structures. The challenge in this
technique is the limitation of long-range defect-free layer
production. In general, 10−100 μm2 defect-free layers are
possible.181 Eﬀorts to increase the defect-free synthesis range
are continuing; e.g., large area defect-free nanohole arrays
fabricated by NSL have been demonstrated.182 Brieﬂy, single or
double layer ordered hexagonal arrays of polymer nanospheres
are self-assembled on the substrate. Then, a metal layer is
deposited on the nanosphere mask by thermal evaporation,
pulsed laser deposition, or electron beam deposition. The
interstices between the nanospheres allow some of the metal to
reach to the substrate, creating an array of metal nanoparticles
on the surface. Finally, the nanosphere layer(s) is/are removed
by sonicating the sample in a solvent.181 With variants of this
technique, a wide variety of nanoshapes were fabricated in array
format, including prisms, cubes, triangles, disks, and pyramidal
structures.80
An earlier use of LSPR for clinical purposes has been through
the detection and conﬁrmation of a biomarker related to
Alzheimer’s disease.183 LSPR spectroscopy was used to detect
the interactions of the amyloid-derived diﬀusible ligand
(ADDL) biomarkers with anti-ADDL antibodies. First, an
array of Ag particles (∼90 nm in width, ∼25 nm in height) was
synthesized on the substrate using the NSL technique described
above. Then, the nanoparticles were activated with the ﬁrst
anti-ADDL antibody of a sandwich assay while also blocking
the Ag particles for nonspeciﬁc binding. Samples were exposed
to various concentrations of ADDLs. Finally, the sample was
incubated in the second anti-ADDL antibody to improve the
extinction signal. UV−vis spectroscopy was used to monitor the
extinction signal. The experiments on cerebrospinal ﬂuid from
patients with Alzheimer’s disease showed an LSPR extinction
signal shift with respect to the control patients. The experiment
supported previous observations of elevated ADDL concen-
trations in the cerebral ﬂuids of patients with Alzheimer’s
disease and demonstrated the potential of LSPR in medical
applications.
Further examples of LSPR biosensing were given in peptide
nucleic acid−DNA hybridization,184 label-free DNA biosens-
ing,185 streptavidin−biotin interactions on gold nanorods,186
aptamer−protein interactions,187 and in detection of Escherichia
coli,188 PSA,189 serum p53 protein, which is involved in head
and neck squamous cell carcinomas,190 and p53 gene
mutation.191
Further, LSPR has applications in cancer diagnosis. An LSPR
experiment utilizing a microspectrometer to detect oral
epithelial cancer cells has been demonstrated.192 The
researchers used two epithelial malignant cell lines of human
oral squamous cell carcinoma, HOC 313 clone 8 and HSC 3,
and one nonmalignant cell line, HaCaT, human keratinocytes.
The LSPR spectra from colloidal gold nanoparticles conjugated
to monoclonal antiepidermal growth factor receptor (anti-
EGFR) antibodies after incubation in cell cultures with the
HaCaT cell line and the two malignant oral epithelial cell lines
were measured. LSPR scattering images were also acquired by
dark-ﬁeld microscopy and used to demonstrate that antibody
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Figure 9. The distribution of six diﬀerent antibodies corresponding to nine concentrations from 1 fg/mL to 1 mg/mL is shown along with the
reﬂection-mode, intensity-based LSPR detection method. Reprinted with permission from ref 193. Copyright 2006 American Chemical Society.
Figure 10. A microﬂuidic-based LSPR system. (A) The gold-nanosphere-coated LSPR channel and the control channel are positioned next to each
other in the photograph of the microchip. (B) The experimental schematic indicating the LED light source, microﬂuidic chip, and photodetector.
(C) Atomic force microscopy (AFM) and transmission electron microscopy (TEM) images of the nanoparticles on the chip. Reprinted with
permission from ref 194. Copyright 2009 Springer.
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conjugated gold nanoparticles homogenously and speciﬁcally
attached on the malignant cell surfaces, whereas the nano-
particles nonspeciﬁcally and randomly bound to HaCaT cell
surfaces. Thus, both the extinction measurements and the dark-
ﬁeld images were shown to be potentially useful in cancer
diagnostics.
Diagnostic LSPR applications for infectious diseases are also
being developed. A recent LSPR application was reported to
capture, detect, and quantify multiple HIV subtypes (A, B, C,
D, E, G, and subtype panel) from unprocessed whole blood and
phosphate-buﬀered saline (PBS) without any sample prepro-
cessing.56 In this study, polystyrene surfaces were ﬁrst coated
with poly-L-lysine molecules to immobilize gold nanoparticles.
Then, speciﬁc surface chemistry was utilized to capture multiple
HIV subtypes spiked in whole blood and PBS samples, and the
limit-of-detection was observed down to 98 ± 39 virus copies/
mL for HIV subtype D. Further, the nanoplasmonic platform
was validated with eight HIV-infected anonymous discarded
patient whole blood samples, and LSPR response was
converted to viral load in order to correlate with gold standard
method (i.e., RT-qPCR) using Bland−Altman analysis. This
statistical analysis between the nanoplasmonic platform and
RT-qPCR counts displayed that there was no evidence for a
systematic bias for HIV-infected patient blood samples. To
evaluate the repeatability of the presented platform, a
repeatability parameter was deﬁned as the percent variation
in wavelength shift values for the same virus concentration, and
the platform presented a high repeatability (up to 90%),
sensitivity, and speciﬁcity to capture multiple HIV subtypes
from unprocessed whole blood and whole blood samples from
HIV-infected patients. This nanoplasmonic technology pre-
sented a versatile, broadly applicable platform, which is capable
of detecting other pathogens with reasonably well-described
biomarkers available, and could be performed at multiple
settings including POC settings and primary care settings.
Microﬂuidic-based platforms are being developed for multi-
plexed analysis of various biomarkers. An LSPR-based multi-
array nanochip for massively parallel detection was reported
(Figure 9).193 The nanochip was constructed by a core−shell
structured nanoparticle layer. Surface-modiﬁed, 100-nm-diam-
eter silica nanoparticles were sandwiched between two layers of
gold deposited by thermal deposition. Glass slides were used as
substrates for gold deposition. The bottom layer was made of 5-
nm-thick chromium and 40-nm-thick gold layers, and the layer
on top of the silica was made of a 30-nm-thick gold layer.
Speciﬁc antibodies were then immobilized on the 300 spots
each with a 100 nL volume, using a nanoliter dispensing
system. In this work, six diﬀerent antibodies on 50 spots each
were immobilized. After 30 min incubation with six antigens of
varying concentrations, immunoglobulins A, D, G, and M (IgA,
IgD, IgG, and IgM); C-reactive protein (CRP); and ﬁbrinogen
were detected by an LSPR setup operating in the reﬂection
mode. It should be noted that the measurements were
absorbance intensity changes in the peak wavelength instead
of the more common wavelength shifts. A sensitivity of 100 pg/
mL for all proteins and a linear signal dependence up to 1 μg/
mL were reported. This easy-to-operate, multiplexed, rapid
technique has prospects in future POC technologies when
applied to various biomarkers.
Another LSPR-based biosensor with fully integrated micro-
ﬂuidics is shown in Figure 10.194 The platform comprises a
gold-nanoparticle-coated quartz surface for the sensor channel
and a blank quartz surface without nanoparticles serving as the
reference channel. The diameter of gold nanoparticles was
optimized with three-dimensional ﬁnite-diﬀerence time-domain
(3-D FDTD) simulations. The gold nanoparticles were
immobilized on the sample channel substrate by using silane
modiﬁcation. In this platform, the binding of biotin to
antibiotin antibody was evaluated. The immobilization of
biotin on a self-assembled monolayer of thiol and the following
binding of antibiotin were monitored in real-time by the LSPR
signal. A 530 nm LED was used as the light source, and a
photodiode was used as the detector. The collimated and
focused light incident on the sample channel excites LSPR
modes of the gold nanoparticles, and the remaining light
transmitted to the photodiode was used to collect real-time
binding analysis data. A resolution of 10−4 in refractive index
corresponding to an antibiotin detection limit of 270 ng/mL
was achieved. The resolution of the microﬂuidic LSPR system
was comparable to that of conventional LSPR biosensors.73
Generalization of this system to other biomolecules is possible,
and with a versatile and compact design, it has many prospects
in various POC settings.
5.3. Surface Plasmon Resonance Imaging (SPRi)
The early demonstrations of SPRi aimed at providing better
resolution over microscopic techniques such as phase contrast
microscopy or interference contrast microscopy.195 SPRi is a
high-throughput optical detection method similar to the
sensogram-based SPR techniques in principle, but the detection
step allows imaging potentially tens of channels in parallel. A
monochromatic or narrow-pass ﬁltered light passing through a
prism, which is typically conﬁgured in the Kretschmann
conﬁguration, is incident on the activated thin metal surface
close to the surface plasmon resonance angle. Binding of the
analytes will induce a refractive index change in a vicinity close
to the metal, allowing for the incoming light to couple to the
surface plasmon modes and lose some energy to the
propagating surface plasmon polaritons. This energy loss will
be observed as a change in the intensity of the reﬂected light.
Since the binding to activated sites on the metal causes local
refractive index changes, this spatial information will be
transferred to the reﬂected light. Thus, the captured images
will allow for temporal and spatial monitoring of surface
binding events in a label-free setup, allowing for adsorption and
desorption kinetic measurements and highly sensitive bio-
recognition experiments.196
Earlier reported work in this area was in analyzing nucleic
acid hybridization, enzyme kinetics, and protein−DNA
interactions.197 Surface functionalization techniques for high-
throughput array-based SPRi detection, involving carbohy-
drate−protein interactions, protein−peptide interactions, and
protein−protein interactions, were developed.198 RNA hybrid-
ization on DNA surface arrays was shown, at around 10 nM
detection limit.199 With enzyme ampliﬁcation using RNase H,
the detection limit was improved from 1 nM to ∼1 fM for
DNA hybridization on RNA microarrays.200 The technique
utilizes the fact that RNase H enzyme selectively and repeatedly
destroys RNA from the DNA−RNA heteroduplexes on gold
surfaces, releasing the DNA back into the solution and resulting
in a six orders of magnitude improvement in the detection
limit.
Enzyme reactions have been observed with SPRi, such as the
base excision repair (BER) reaction and the activity of the DNA
N-glycosylases enzyme. This enzyme is crucial in the major
mechanism of the nucleobase error correction mechanism,
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since a decrease in its activity leads to carcinogenesis and
aging.201 An SPRi experiment reported the recognition of
several damaged DNA nucleobases and the screening for
inhibitors of DNA repair proteins.202 Aptamers, natural or
engineered nucleic acids and peptides, have also been used in
conjunction with the SPRi technique. For instance, in
aptamer−protein interaction studies, detection platforms for
human factor IXa,203 vascular endothelial growth factor,204 and
human immunoglobin E205 were reported.
An SPRi system with a HeNe laser as a light source was
developed to study the protein-binding kinetics of double-
stranded DNA on a 10 × 12 array of planar gold surface. Using
this system, a refractive index change of 1.8 × 10−5 RIU was
observed.206 The improvement of this system led to the
detection of an eﬀective refractive index change of 5 × 10−6
RIU on a 300 spot protein array with 200 μm spot size and 1 s
temporal resolution.207 Another SPRi system based on a
tunable light source was shown to be sensitive to a refractive
index change of 3 × 10−5 RIU.208 The imaging technique was
investigated with a polarization contrast approach to acquire
high-contrast images. This was accomplished by ﬁltering the
light reﬂected from the inactive areas. This system showed a
sensitivity of around 3 × 10−6 RIU in refractrometric
experiments, and the sensor could provide 64 simultaneous
measurements with a limit of detection of 100 pM for 23-mer
oligonucleotides.209
Recently, high-throughput and integrated microﬂuidic
applications of SPRi have gained considerable attention.
These systems provide the integration of various elements
required for the on-chip applications. For example, a micro-
ﬂuidic chip with microchannels, microvalves, micropumps, ﬂow
sensors, and an on-chip temperature controller was developed
with MEMS technology. The chip comprised three layers of
PDMS, carrying these structures on a glass substrate. The
system has been demonstrated through the detection of
interaction between IgG and antirabbit IgG, and a detection
limit of 1 × 10−4 mg/mL (0.67 nM) was observed.210
SPRi measurements of antibody arrays for larger molecules,
such as mouse KIAA proteins (MW ∼130 kDa)211 and proteins
in cell lysates,212 bovine serum albumin (MW ∼69 kDa), and
bovine IgG (MW ∼150 kDa),213 were followed by measure-
ments for lighter biomarkers (MW ∼10 kDa). For instance, a
high-density multiplexed antibody array was combined with the
SPRi technique, to detect low molecular weight protein
biomarkers (Figure 11).214 One-step carbonyldiimidazole
(CDI) surface chemistry was used to attach β2-microglobulin
(MW ∼11.8 kDa) and cystatin C (MW 13.4 kDa) biomarkers
on functionalized gold surfaces. The created antibody micro-
array comprised array element sizes between 750 μm and 200
μm. The SPRi system was able to detect these biomarkers with
a sensitivity of down to ∼1 nM.
A recent advance is the development of a microﬂuidic chip
for immunoassay-based SPRi.215 The system, shown in Figure
12, was comprised of two levels. The “ﬂow channel” level was
comprised of a crossed-ﬂow architecture, allowing for loading
two sets of reagents simultaneously. A second level, the
“control channel”, hosted microﬂuidic pumps for controlling
the liquid ﬂow in the ﬂow channel. The lower layer crossed-
channels have a width of 100 μm and a height of ∼10 μm, and
their intersection is located over surface-activated gold spots
with 250 μm diameters and ∼50 nm thickness, where the
immunoreactions take place. These layers were fabricated
through photolithographic techniques on PDMS and were
attached to each other with the dipping−attaching method.216
In the setup, p-polarized incoming light (625 nm) passes
through a prism and hits on the gold areas. The reﬂected light
emerges from the prism and is collected by a home-made digital
imaging device. To demonstrate the detection performance of
the chip, ﬁrst a one-step immunoassay examined the binding of
anti-biotin antibodies to biotinylated bovine serum albumin
(biotin−BSA), as an antibody−antigen pair. A group of biotin−
BSA/BSA solutions with diﬀerent concentrations was injected
in horizontal channels, resulting in adsorption of biotin−BSA/
BSA on the gold surfaces. Then, known concentrations of anti-
biotin solutions were injected in the vertical channels, creating
immunoreactions with the immobilized biotin−BSA. The
immunocomplex formation was related to both the biotin−
BSA concentration on the surface and to the anti-biotin
antibody. Real-time immunoassay imaging allowed for mon-
itoring of each immunoreaction in about 10 min, and the
system attained a sub-nanomolar detection limit. Next, a two-
level immunoassay was utilized for signal ampliﬁcation. Another
antibody, anti-goat IgG antibody, labeled with gold nano-
particles was delivered to the gold spots. This improved the
limit of detection down to ∼40 pM. With its small instrument
dimensions of ∼2−3 cm and with less than 100 pM detection
performance as a microscale platform, this SPR imaging system
has potential for future POC applications.
To increase the unit addressing capability in a crossed-ﬂow
geometry, a microﬂuidic chip with individually addressable
chambers was developed (Figure 13).217 The design allows for
parallel interrogation of multiple analytes with multiple ligands
on an SPRi setup. The chip has two levels similar to the
microchip developed in ref 215. The lower level contains the
ﬂow channels (100 μm wide by 10 μm high) and the upper
level contains microvalves (100 μm wide by 150 μm long)
isolating and controlling the liquid ﬂow and a micropump to
pump the liquid. The chip is comprised of six columns and an
array of 11 groups each with four chambers, totaling 264
chambers. To load an individual chamber, ﬁrst the liquid is
gated to a four chamber group and then four chamber valves
open or close to address the liquid to an individual chamber.
After loading the required chambers, the valves for those
Figure 11. SPRi detection of 50 nM β2-microglobulin (β2m) and 100
nM cystatin C (cysC). (A and C) Images for β2m and cysC detection,
respectively. (B) The line proﬁles indicated in parts A and C show
signal only in the corresponding channels where the antibodies were
positioned. (D) Map of the antibodies and control channels used in
parts A and C. Reprinted with permission from ref 214. Copyright
2006 American Chemical Society.
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chambers are closed and the remaining liquid is washed out.
With this method, up to 264 diﬀerent ligands can be
immobilized in the system. The chip also comprises a serial
dilution network for analytes, allowing dilutions of samples up
to six diﬀerent concentrations for interrogations.
To test the performance of the chip, a human α-thrombin
immunoassay was conducted. The biotinylated human α-
thrombin was immobilized in a predetermined manner, taking
advantage of the element-addressability of chambers. Antihu-
man α-thrombin antibody was injected at diﬀerent concen-
Figure 12. A microﬂuidic-based SPRi platform. (A) Schematic of the microchip for the SPRi experiment. The lower layer is where the
immunoreactions take place, and the upper layer controls the ﬂuid ﬂow by microﬂuidic pumps. (B) The microﬂuidic device with dyed ﬂuids to
illustrate the microchannels. Figures are courtesy of Prof. Richard N. Zare.
Figure 13. Layout of the element addressable microdevice for SPRi experiments, depicting the 264 chamber microarray, accessed by various features,
such as a micropump, microvalves, micromixers, input/output channels, and a row multiplexer. A detailed microarray is shown along the photograph
of the microﬂuidic chip. Figures are courtesy of Prof. Eric T. Lagally.
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trations. The binding of the antibody and its kinetics were
successfully observed in the SPRi sensogram data. Further, two
immunoassays were simultaneously performed to demonstrate
the multiplexed nature of the chip. Human factor IX proteins
were immobilized in 44 element-addressable chambers and
human α-thrombin proteins were immobilized in another set of
44 element-addressable chambers. In addition, using ﬂuores-
cent-labeled antibodies in conjunction with SPRi sensograms,
the ability to recover bound species from individual chambers
was demonstrated. This SPRi device architecture could be used
in future high-throughput medical applications.
An important SPRi advance recently reported individual virus
particle detection. An SPRi device was developed, based on the
Kretschmann conﬁguration, that incorporated a high numerical
aperture (NA = 1.65) objective to image single viruses.218 An
SPR chip was placed on the objective with index matching oil,
as shown in Figure 14. Then, 632.8 nm of laser light from a
HeNe laser or 680 nm superluminescence diode light was p-
polarized and inserted in the optical path to excite surface
plasmons on the gold surface. The SPRi images allowed the
imaging of individual inﬂuenza A virus binding events on
antibody-functionalized gold surfaces. Nanoparticles of known
sizes and estimated refractive indices were used for calibration
curves, intensity−volume curves were plotted, and volumetric
information for the inﬂuenza A virus was extracted. Using the
known density of inﬂuenza A virus, diameter of the virus was
calculated as 109 ± 13 nm, corresponding to a mass of 0.80 ±
0.35 fg. Human cytomegalovirus (HCMV) was also studied
with the setup and the virus diameter was extracted as 218 ± 10
nm, corresponding to a mass of 6.5 ± 0.8 fg.
6. CONCLUSION AND FUTURE OUTLOOK
Plasmonic-based biosensor technologies can be used in
diﬀerent economic settings for diagnostic testing, such as (i)
“high-income, centralized”; (ii) “high-income, POC”; (iii) “low-
income, centralized”; and (iv) “low-income, POC”.4 High-
income, POC is exempliﬁed by bedside diagnostic tests and
disaster or bioemergency response in developed countries.
Low-income, POC can be rural health clinics with basic
infrastructure or isolated village health service providers. These
conditions impose diﬀerent levels of constraints on diagnostic
device engineering and design. For instance, material choice,
storage, transportation, ﬂuid control, sample mixing, and
disposal need to be tailored for targeted POC conditions and
applications. Interdisciplinary research eﬀorts are beneﬁcial to
address all these issues for diagnostic device design at the POC.
The research eﬀorts in developing technological platforms
for POC are positioned at the cross-roads of multiple
disciplines. “Convergence” of multiple research ﬁelds is
emerging as a new paradigm in science, indicating the synergy
between engineering, physical sciences, and life sciences.219
Cross-disciplinary pollination among chemistry, biology,
electrical engineering, optics, and biotechnology is transforming
each ﬁeld and creating new ways of doing engineering and
performing fundamental life science research, as well as
providing new potential clinical applications. The LOC devices
with integrated nanoplasmonic and microﬂuidic components,
inexpensive fabrication techniques, and reliable read-outs for
portable commercial POC platforms will be a part of this
transformation. We believe that the progress in the micro-
ﬂuidics ﬁeld converging with optics, electronics, and bioengin-
eering will greatly enhance the human health through
generating inexpensive, rapid, portable, and sensitive platform
technologies.
Future robust and easy-to-operate POC testing systems will
also support the personalized medicine eﬀorts.220 For instance,
the development of reliable bedside technologies for medical
diagnosis of infectious diseases would have a great impact in
disease monitoring and control. The current bedside testing
devices are exempliﬁed by disposable immunochromatographic
strip tests.7,221 Integrated microﬂuidic−plasmonic technologies
can be potentially utilized at the bedside for various diseases,
including examples such as hepatitis, sepsis, pneumonia, cancer,
and AIDS. We envision that these technologies will play an
important role in infectious disease detection and monitoring at
the POC, bedside, and primary care settings.
Another area with an unmet diagnostic need is immuno-
diagnostics.222 Detection of protein markers can help diagnose
conditions such as cancer, metabolic diseases, or cardiovascular
diseases. Technologies sensitive to these proteins can be used
for monitoring disease progression, therapy, or early
diagnosis.222 Other areas that could potentially beneﬁt from
the development of microﬂuidic POC platforms include toxin
monitoring, food safety, drug discovery, and proteomics
research.18a
One of the challenges from a POC perspective has been
transferring prototype plasmonic-based technologies from the
laboratory settings to clinical use. In the case of LSPR,
development of sensitive, portable, and inexpensive spectrom-
eters will assist this transformation. Portable spectrometers are
already becoming available in the market.223 Periodic or quasi-
periodic metal nanoarrays, nanoholes, and nanoparticles with
engineered electromagnetic ﬁeld enhancement properties can
Figure 14. SPRi system used for individual virus particle imaging. (A) The schematic for the SPRi experiment utilizing an objective in the
Kretschmann conﬁguration and an inverted microscope. (B) SPR images of the inﬂuenza A virus in PBS buﬀer. Reprinted with permission from ref
218. Copyright 2010 National Academy of Sciences.
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provide enhanced localized surface plasmon excitation and
detection capabilities.71,224 The translation of LSPR technolo-
gies depends on their compatibility with batch-fabrication to
enable inexpensive devices. Currently, nanohole or similar
periodic nanoarray systems require expensive lithographic
methods that are limited by throughput. Some of the recent
LSPR approaches that use self-assembly of gold nanoparticles,
which are compatible with 96-well and microﬂuidic chip
systems, are promising for applications in infectious disease and
early cancer detection both in developed and developing
settings.56 Therefore, future advances in nanotechnology are
likely to provide signiﬁcant improvements in LSPR-based
biomedical devices.
SPR technology has been commercialized, most notably by
Biacore’s and KSV Instruments’ SPR series. The technological
challenges eﬀecting SPR-based technologies for POC diag-
nostic applications include generating substrates that will
present reproducible results from batch to batch, integrating
the systems for portability, and adapting the systems for use
with bodily ﬂuids. Developing diagnostic platforms that will
operate at the POC will require adapting SPR-based
technologies to be used as a versatile, inexpensive, and portable
platform. Flexible substrates such as paper-based printed chips
or microﬂuidic cartridges operating with portable readers will
help translating SPR devices. Further, the electronics industry is
consistently creating more aﬀordable and rapid optical
detectors and improved networked devices. Recently, smart-
phones spread around the world rapidly. Considering the
possibilities of using built-in sensors or cameras in smart
phones as a part of integrated microﬂuidics platforms, it is
conceivable that the next-generation SPR devices will penetrate
into global markets and households. In particular, smartphone
penetration in Africa can be leveraged for POC device
distribution, where these devices can be utilized as a reader
component for biosensing applications.225,226,227
We expect that microﬂuidic platforms, plasmonic technolo-
gies, and surface functionalization techniques integrated in
reliable and sensitive lab-chip applications will continue to serve
clinical needs and patients. The development of immunoassays
and further integration of these assays with microﬂuidic
technologies and emerging portable optical technologies have
the potential to enable applications that will beneﬁt both the
resource-constrained and the developed world settings,
targeting real world clinical problems and diseases including
cancer and infectious diseases.
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